CDKL2抗体;CDKL2 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue lysate, Primary antibody: P13051(CDKL2 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13051(CDKL2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P13051(CDKL2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The CDKL2 (Cyclin-Dependent Kinase-Like 2) antibody is a tool used to study the CDKL2 protein, a member of the CDKL family, which shares structural similarities with CDKL5. CDKL2 is a serine/threonine kinase implicated in regulating cellular processes such as cell cycle progression, signal transduction, and neuronal development. Though less studied than CDKL5. CDKL2 is believed to interact with substrates involved in microtubule dynamics and synaptic plasticity. Its expression is observed in various tissues, including the brain, with potential roles in neurodevelopment and cancer. Dysregulation of CDKL2 has been loosely associated with cancers (e.g., breast, lung) and neurological disorders, though direct mechanistic links remain under investigation.

CDKL2 antibodies are primarily used in research to detect protein expression, localization, and post-translational modifications via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate CDKL2's functional pathways and its interplay with other kinases or disease-related proteins. Commercial CDKL2 antibodies are typically raised in hosts like rabbits or mice, with both polyclonal and monoclonal options available. Validation often involves knockout cell lines or siRNA-mediated silencing to confirm specificity. Researchers emphasize the need for rigorous validation due to cross-reactivity risks with homologous kinases like CDKL1 or CDKL5. As interest grows in CDKL family proteins as therapeutic targets, CDKL2 antibodies remain critical for advancing understanding of its biological and pathological significance.